Ken Griffin Biocryst Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 139,800 shares of BCRX stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

139,800

Previous 95,400 46.54%

Holding current value

$1.06 Million

Previous $589,000 80.31%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $248,938 - $337,484	-38,836 Reduced 12.21%	279,143 $2.12 Million
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $652,102 - $1.07 Million	157,894 Added 98.63%	317,979 $1.97 Million
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $1.02 Million - $1.6 Million	-209,551 Reduced 56.69%	160,085 $813,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $5.04 Million - $6.85 Million	-1,011,234 Reduced 73.23%	369,636 $2.21 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $2.16 Million - $2.54 Million	321,309 Added 30.32%	1,380,870 $9.78 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $1.08 Million - $1.36 Million	154,491 Added 17.07%	1,059,561 $7.46 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $6.72 Million - $10 Million	846,651 Added 1449.27%	905,070 $7.55 Million
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $9.59 Million - $13 Million	-912,896 Reduced 93.99%	58,419 $670,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $4.63 Million - $6.35 Million	428,854 Added 79.06%	971,315 $12.2 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $736,176 - $1.67 Million	93,305 Added 20.77%	542,461 $5.74 Million
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $587,051 - $1 Million	50,783 Added 12.75%	449,156 $7.3 Million
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $6.23 Million - $8.62 Million	-557,481 Reduced 58.32%	398,373 $5.52 Million
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $1.1 Million - $1.37 Million	-77,449 Reduced 7.5%	955,854 $13.7 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $2.14 Million - $3.89 Million	225,691 Added 27.95%	1,033,303 $16.3 Million
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $41.9 Million - $77.4 Million	-5,688,305 Reduced 87.57%	807,612 $8.21 Million
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $7.31 Million - $18.7 Million	-2,168,814 Reduced 25.03%	6,495,917 $48.4 Million
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $614,048 - $989,997	179,023 Added 2.11%	8,664,731 $29.8 Million
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $4.51 Million - $13.3 Million	2,376,174 Added 38.89%	8,485,708 $40.4 Million
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $245,688 - $631,111	153,555 Added 2.58%	6,109,534 $12.2 Million
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $3.37 Million - $7.32 Million	2,122,508 Added 55.37%	5,955,979 $20.5 Million
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $852,182 - $1.27 Million	340,873 Added 9.76%	3,833,471 $11 Million
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $3.74 Million - $11.7 Million	1,283,723 Added 58.12%	3,492,598 $13.2 Million
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $11 Million - $14.5 Million	1,488,671 Added 206.7%	2,208,875 $0
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $4.34 Million - $6.39 Million	665,917 Added 1226.66%	720,204 $5.81 Million
Q3 2018 Nov 13, 2018	SELL	$5.52 - $7.99 $68,459 - $99,091	-12,402 Reduced 18.6%	54,287 $0
Q2 2018 Aug 10, 2018	SELL	$4.6 - $6.52 $1.82 Million - $2.58 Million	-395,390 Reduced 85.57%	66,689 $0
Q1 2018 May 11, 2018	SELL	$4.35 - $5.82 $4.06 Million - $5.43 Million	-933,468 Reduced 66.89%	462,079 $2.2 Million
Q3 2017 Nov 09, 2017	BUY	$4.1 - $5.97 $5.72 Million - $8.33 Million	1,395,547	1,395,547 $7.31 Million

Others Institutions Holding BCRX

# of Institutions

279

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account